Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Path HoldingsBPTH 3-Year EPS without NRI Growth Rate is 45.60% as of Mar. 2026, which is 891% above its 10-year median of 4.60. The stock has 1 warning sign investors should review. Among 1,157 Biotechnology companies, Bio-Path Holdings ranks better than 81.68% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 45.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 33.40% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 30.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Bio-Path Holdings was 51.20% per year. The lowest was -33.30% per year. And the median was 4.60% per year.
Bio-Path Holdings (OTCPK:BPTH) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Bio-Path Holdings 3-Year EPS without NRI Growth Rate Related Terms
BPTH vs CDT, CLSDQ, ABPO: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Bio-Path Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Path Holdings 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Bio-Path Holdings's 3-Year EPS without NRI Growth Rate falls into.
Bio-Path Holdings 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 45.60% mean?
Bio-Path Holdings (BPTH) has a 3-Year EPS without NRI Growth Rate of 45.60% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bio-Path Holdings and its competitors. This is 891% above median its historical median of 4.60. According to the industry distribution chart, Bio-Path Holdings ranks #212 out of 1157 companies in the Biotechnology industry, placing it in the top 18.3%.
Is Bio-Path Holdings' 3-Year EPS without NRI Growth Rate too high?
Bio-Path Holdings' current 3-Year EPS without NRI Growth Rate of 45.60% is 891% above median its 10-year median of 4.60. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.90. Bio-Path Holdings' value of 45.60% is 186.8% above this industry median. Based on the distribution chart, Bio-Path Holdings ranks #212 out of 1157 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Bio-Path Holdings' 3-Year EPS without NRI Growth Rate compare to CDT and CLSDQ?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #212 out of 1157 companies for 3-Year EPS without NRI Growth Rate. This places Bio-Path Holdings in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 15.90. Bio-Path Holdings' value of 45.60% is 186.8% above this benchmark. While the company's 10-year median is 4.60 vs. the industry median of 15.90, Bio-Path Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.90, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Path Holdings's current 3-Year EPS without NRI Growth Rate of 45.60% is 186.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bio-Path Holdings and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Path Holdings's current 3-Year EPS without NRI Growth Rate is 45.60%, which is 891% above median its own 10-year median of 4.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current 3-Year EPS without NRI Growth Rate of 45.60%. The current 3-Year EPS without NRI Growth Rate is 45.60%, which is 891% above median its 10-year median of 4.60 and 186.8% above the Biotechnology industry median of 15.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current 3-Year EPS without NRI Growth Rate is 45.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BPTH has been successfully added to your 
